Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Hill

Anesthesiology Bluffton, SC Medical Doctor

NPI 1073709077 CMS profile 650254

38 Sheridan Park Circle Suite F, Bluffton, SC 29910

Open in the dashboard

General payments

$7,478

273 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Hill of Bluffton, SC is reported in the CMS Open Payments database as having received $7,478 across 273 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,026 34
2024 General $1,270 58
2023 General $970 42
2022 General $1,440 45
2021 General $1,723 66
2020 General $638 21
2019 General $411 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Hill
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Ryan Hill were reported at $1,026. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Ryan Hill Anesthesiology median Middle half National median
2019 $411 $72 $23–$151 $163
2020 $638 $36 $17–$120 $114
2021 $1,723 $49 $21–$135 $132
2022 $1,440 $52 $22–$144 $149
2023 $970 $53 $23–$143 $160
2024 $1,270 $55 $25–$150 $164
2025 $1,026 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,598 68 payments
  2. Medtronic, Inc. $987 27 payments
  3. Nevro Corp. $982 35 payments
  4. Collegium Pharmaceutical, Inc. $617 39 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $541 37 payments
  6. Abbott Laboratories $432 9 payments
  7. Biodelivery Sciences International, Inc. $172 11 payments
  8. Globus Medical, Inc. $165 7 payments
  9. Stryker Corporation $162 2 payments
  10. Forte Bio-Pharma LLC $149 9 payments
  11. Other $673 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,966 265 payments
  2. Travel and Lodging $431 5 payments
  3. Education $80 3 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $625 22 payments
  2. SPECTRA WAVEWRITER $623 11 payments
  3. Omnia $604 19 payments
  4. WAVEWRITER ALPHA $554 9 payments
  5. RELISTOR $509 35 payments
  6. BELBUCA $497 31 payments
  7. INTELLIS ADAPTIVESTIM $403 11 payments
  8. General - Pain Management $309 6 payments
  9. INCEPTIV $268 5 payments
  10. SYNCHROMEDII $259 7 payments
  11. Other $3,049 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

5,769

Median for Anesthesiology: 322

Drug cost

$423,399

Median for Anesthesiology: $8,738

Branded share of claims

34.9%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 93 $61,539
Belbuca Buprenorphine Hcl Brand 75 $54,969
Buprenorphine Generic 215 $45,343
Oxycontin Oxycodone Hcl Brand 73 $41,919
Relistor Methylnaltrexone Bromide Brand 17 $35,975
Nucynta Tapentadol Hcl Brand 29 $23,865
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 631 $16,992
Savella Milnacipran Hcl Brand 24 $15,086
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 612 $14,820
Movantik Naloxegol Oxalate Brand 29 $13,891

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$408,319

Of which drugs: $9,197

Medicare patients

740

Average age 76

Services billed

54,365

452 women, 288 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 28%
Depression 26%
Diabetes 23%
Chronic kidney disease 20%
Atrial fibrillation 19%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 411 50,093 $5,099
Injection, methylprednisolone acetate, 80 mg J1040 Office 167 183 $1,332
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Q9965 Office 346 860 $955
Injection, methylprednisolone acetate, 40 mg J1030 Office 93 108 $464
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 131 234 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $189
$189 75 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $166
$166 17 —
PROLATE
  • Forte Bio-Pharma LLC $55
$55 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $25
$25 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record